GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BB Biotech AG (GREY:BBAGF) » Definitions » Cyclically Adjusted Price-to-FCF

BB Biotech AG (BB Biotech AG) Cyclically Adjusted Price-to-FCF : 11.43 (As of May. 15, 2024)


View and export this data going back to . Start your Free Trial

What is BB Biotech AG Cyclically Adjusted Price-to-FCF?

As of today (2024-05-15), BB Biotech AG's current share price is $46.50. BB Biotech AG's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $4.07. BB Biotech AG's Cyclically Adjusted Price-to-FCF for today is 11.43.

The historical rank and industry rank for BB Biotech AG's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

BBAGF' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 17.06   Med: 18.67   Max: 22.52
Current: 18.64

During the past years, BB Biotech AG's highest Cyclically Adjusted Price-to-FCF was 22.52. The lowest was 17.06. And the median was 18.67.

BBAGF's Cyclically Adjusted Price-to-FCF is ranked better than
87.62% of 105 companies
in the Biotechnology industry
Industry Median: 57.44 vs BBAGF: 18.64

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

BB Biotech AG's adjusted free cash flow per share data for the three months ended in Dec. 2023 was $-0.020. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $4.07 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


BB Biotech AG Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for BB Biotech AG's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BB Biotech AG Cyclically Adjusted Price-to-FCF Chart

BB Biotech AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 22.51 18.64

BB Biotech AG Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Dec17 Dec18 Dec19 Dec20 Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.51 18.12 18.51 18.18 18.64

Competitive Comparison of BB Biotech AG's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, BB Biotech AG's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BB Biotech AG's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BB Biotech AG's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BB Biotech AG's Cyclically Adjusted Price-to-FCF falls into.



BB Biotech AG Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

BB Biotech AG's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=46.50/4.07
=11.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BB Biotech AG's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, BB Biotech AG's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.02/106.4611*106.4611
=-0.020

Current CPI (Dec. 2023) = 106.4611.

BB Biotech AG Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201106 0.000 102.678 0.000
201109 1.095 101.811 1.145
201112 0.382 101.408 0.401
201203 1.698 101.826 1.775
201206 -0.133 101.596 -0.139
201209 2.532 101.392 2.659
201212 0.387 100.968 0.408
201303 1.053 101.221 1.108
201306 1.977 101.466 2.074
201309 -0.642 101.336 -0.674
201312 1.421 101.036 1.497
201403 -0.232 101.224 -0.244
201406 0.065 101.517 0.068
201409 0.431 101.247 0.453
201412 1.945 100.704 2.056
201503 3.209 100.339 3.405
201506 2.873 100.464 3.045
201509 -3.508 99.785 -3.743
201512 -1.522 99.386 -1.630
201603 -0.393 99.475 -0.421
201606 0.272 100.088 0.289
201609 2.280 99.604 2.437
201612 0.015 99.380 0.016
201703 0.945 100.040 1.006
201706 5.973 100.285 6.341
201712 0.000 100.213 0.000
201812 0.000 100.906 0.000
201912 0.000 101.063 0.000
202012 0.000 100.241 0.000
202103 -1.943 100.800 -2.052
202106 1.000 101.352 1.050
202112 0.000 101.776 0.000
202203 4.308 103.205 4.444
202206 0.699 104.783 0.710
202209 0.618 104.835 0.628
202212 -1.180 104.666 -1.200
202303 4.002 106.245 4.010
202306 0.173 106.576 0.173
202309 0.151 106.570 0.151
202312 -0.020 106.461 -0.020

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BB Biotech AG  (GREY:BBAGF) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


BB Biotech AG Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of BB Biotech AG's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


BB Biotech AG (BB Biotech AG) Business Description

Industry
Traded in Other Exchanges
Address
Schwertstrasse 6, Schaffhausen, CHE, CH-8200
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market and is one of the largest investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. BB Biotech follows a strategy of carefully screening and selecting biotechnology firms with a long-term time horizon and having established products in the marketplace. Geographically it earns key revenue from the Netherlands.

BB Biotech AG (BB Biotech AG) Headlines

No Headlines